Although immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors trigger anticancer immune responses, which have been proven useful in the clinical treatment of a series of cancer types [28–30], the application of these reagents is severely restricted in gastric cancer [31, 32]. This evidence concerns the gene CD274 and cancer.